Exscientia and Sanofi enter agreement on bispecific small-molecule drugs for metabolic disease May 9, 2017
TherapeuticsMD receives complete response letter from FDA for TX-004HR as treatment of dyspareunia May 9, 2017
Dauntless Pharmaceuticals reports promising phase I results for intranasal octreotide acetate May 5, 2017
Rhythm advances setmelanotide program into phase III for pro-opiomelanocortin deficiency obesity May 5, 2017
Poxel reports promising topline data from Japanese phase IIb study of imeglimin for type 2 diabetes May 4, 2017
RSS